Summary of meta-analysis of pharmacotherapy trials in BPD https://www.cochrane.org/CD005652/B Meta-analyses of RCTs were undertaken for the following outcomes: BPD symptoms, mental state outcomes (general psychopathology, anger, hostility, irritability, depression, anxiety and suicidal ideation), self-harm and suicide, psychosocial functioning (general functioning, interpersonal and social functioning), and hospitalisation. The meta-analyses included placebo-controlled Managing BPD Clinical Practice Guideline for the Management of Borderline Personality Disorder 67 National Health and Medical Research Council pharmacotherapy trials and psychological intervention trials that compared the study treatment with ‘treatment as usual’. It considered for inclusion all trials identified in the UK national BPD clinical practice guideline1 and the updated systematic review. Findings are summarised in Tables 5.2 and 5.4 #EBM #Management #Pharmacology #BPD #Borderline #Personality #Disorder #Medications #Pharmacotherapy #Effectiveness #Table
